NCT05899608Phase 3Active not recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Study sponsor: Summit Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-12-31Estimated
Enrollment · participants1600Estimated
Source updated2026-10-08Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 2 fields changed

Planned enrollment increased by 520 participants

Before: 1080 participants (planned). After: 1600 participants (planned).

Primary completion date changed

Before: 31 Dec 2027. After: 31 Dec 2028.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview